Full Press Release Details
Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders
recaps key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond
PRAIRIE, Minn., June 2, 2022 (PR Newswire) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne"
or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering
from neurological disorders, today announced the publication of the 2022 Annual Letter to Shareholders published in the Company's
Proxy Statement for its Annual Meeting of Stockholders that occurred on May 31, 2022. The letter may be accessed here.
letter recaps the key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond directed at developing
the Evo platform thin film electrode technology for patients suffering from epilepsy, chronic back pain, and Parkinson's
his letter, Dave Rosa, Chief Executive Officer of NeuroOne, states, "As we continue to develop our platform thin film electrode
technology, we remain confident it will represent a transformational tool for neurosurgeons and neurologists. . I believe we
are on the right path to creating a meaningful impact in patients' lives and have been encouraged by positive feedback from physicians
and patients who are excited to see our products in the market."
from Fiscal Year 2021:
for Fiscal Year 2022 and Beyond:
Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions
for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential
tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce
procedural costs. For more information, visit https://www.n1mtc.com .
press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in
this presentation may be a forward-looking statement that reflects NeuroOne's current views about future events and are subject
to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements
to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify
forward-looking statements by the words or phrases "may," "might," "will," "could," "would,"
"should," "expect," "intend," "plan," "objective," "anticipate," "believe,"
"estimate," "predict," "project," "potential," "target," "seek," "contemplate,"
"continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable
terminology intended to identify statements about the future. Forward-looking statements may include statements regarding the timing
of the Company's submission of its revised 510(k) clearance request for its Evo sEEG Electrode for less than 30-day use, applications
for, or receipt of, regulatory clearance, the Company's ability to submit a special 510(k) clearance request, the timing and extent
of product launch and commercialization of our technology, the completion of research and development of our ablation system, the development
of an electrode for chronic stimulation, the ability to build a world class management team, the expansion of new indications for chronic
use electrodes, expected negotiations with Zimmer Biomet, exploration of complementary technology and partnerships, what the future may
hold for electrical stimulation and NeuroOne's potential role. Although NeuroOne believes that we have a reasonable basis for each forward-looking
statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations
of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors
largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market
acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all, whether
due to supply chain disruptions, labor shortages, the impact of COVID-19 or otherwise; risks that our technology will not perform as
expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital
requirements to achieve its business objectives and ability to raise additional funds; the risk that the COVID-19 pandemic will continue
to adversely impact our business; the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology;
uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions
of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology;
risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual
property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors"
in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this
press release and NeuroOne undertakes no obligation to revise or update any forward-looking statements for any reason, even if
new information becomes available in the future.
Federal law restricts this device to sale by or on the order of a physician"